Jaguar Health, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Jaguar Health executed multiple exchanges in September 2026: (1) Lincoln Alternative Strategies LLC exchanged a $175.0K convertible note for 557,377 common shares (9/11/26); (2) Streeterville Capital LLC exchanged preferred shares for 304,473 common shares across three transactions (7/7/26, 9/11/26, 9/14/26); (3) Joshua Mailman purchased 535,000 common shares and 2,077,255 pre-funded warrants for 284,653 shares of Napo Therapeutics (subsidiary holding) on 9/15/26. Total common shares issued: ~2,077,255 from warrant exercise potential plus ~861,850 from direct exchanges. All transactions utilized Section 3(a)(9) exemption; warrants exercisable at $0.0001/share starting 9/15/26.
Why this rating
Major dilution event—~2.9M shares issued/reserved against $3.8M market cap represents ~76% dilution. Highly material for micro-cap; converts existing debt/preferred into freely tradeable common stock, flooding market.
Tradability signal
NO TRADE
No trade: price $0.23 is below our $0.5 floor — spreads at this level eat any edge.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.23 ▼ 0.00% | at our read · unknown $0.23 | +10 min · unknown $0.22 ▼ 2.35% | +30 min · unknown $0.22 ▼ 2.49% | +1 hr · unknown $0.22 ▼ 0.40% | +4 hrs pending |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.